Two tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors

Hanin, Aurelie; Culligan, Eamonn P.; Casey, Pat G.; Bahey-El-Din, Mohammed; Hill, Colin; Gahan, Cormac G. M.
February 2014
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • Immunotherapy: past, present and future. Waldmann, Thomas A. // Nature Medicine;Mar2003, Vol. 9 Issue 3, p269 

    Reviews related literature on major strategies for the development of effective immunotherapies for the treatment of established infectious diseases and cancer. Prophylactic and therapeutic vaccines; Vaccines for chronic diseases; Vaccine vectors; Enhancing the function of antigen-presenting cells.

  • Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Huadong Pei; Jingfang Liu; Yun Cheng; Chaomin Sun; Chen Wang; Yueping Lu; Jie Ding; Jian Zhou; Hua Xiang // Applied Microbiology & Biotechnology;Aug2005, Vol. 68 Issue 2, p220 

    The nucleocapsid (N) protein of the severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) is an important antigen for the early diagnosis of SARS and the development of vaccines. It was expressed in Escherichia coli as a fusion with human glutathione S-transferase (hGST) and...

  • Systems biology applied to vaccine and immunotherapy development.  // BMC Systems Biology;2011, Vol. 5 Issue 1, p146 

    The article focuses on recent advancements related to the use of systems biology in the study and evaluation of strategies for immunotherapy and vaccination for infections and neoplastic diseases. It offers updates related to the use of systems biology in recent vaccine developments, including...

  • Commentary: Cancer Immunotherapy: How to Bell the Cat? Guha, Chandan; Chowdhury, Jayanta Roy // Einstein Quarterly: Journal of Biology & Medicine;1998, Vol. 15 Issue 1, p47 

    Comments on an article by Howard Kaufman and his colleagues about the development and status of cancer vaccines, published in the 1998 issue of the 'Einstein Quarterly Journal of Biology and Medicine.' Advantages and disadvantages of potential vectors; Ways to avoid immune response against the...

  • Preface. Bhalla, Prem L.; Singh, Mohan B. // Inflammation & Allergy - Drug Targets;Jan2006, Vol. 5 Issue 1, p1 

    Type 1 allergic diseases (allergic rhinitis or hay fever, rhinoconjunctivitis, allergic asthma and allergic dermatitis) are a global health problem and are the most common cause of chronic ill health in the western societies. These allergic diseases have increased in prevalence during the past...

  • Efficient production of secreted staphylococcal antigens in a non-lysing and proteolytically reduced Lactococcus lactis strain. Neef, Jolanda; Koedijk, Danny; Bosma, Tjibbe; Dijl, Jan; Buist, Girbe // Applied Microbiology & Biotechnology;Dec2014, Vol. 98 Issue 24, p10131 

    Cell surface-exposed and secreted proteins are attractive targets for vaccination against pathogenic gram-positive bacteria. To obtain sufficient amounts of such antigens, efficient protein production platforms are needed. In this study, a pipeline for the production and purification of...

  • Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market. Chung-Jr Huang; Lowe, Adam; Batt, Carl A. // Applied Microbiology & Biotechnology;Jun2010, Vol. 87 Issue 2, p401 

    Recombinant immunotherapeutics are important biologics for the treatment and prevention of various diseases. Immunotherapy can be divided into two categories, passive and active. For passive immunotherapy, the successes of antibody and cytokine therapeutics represent a promising future and...

  • Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins. Bahey-El-Din, Mohammed; Gahan, Cormac G. M.; Griffin, Brendan T. // Current Gene Therapy;Feb2010, Vol. 10 Issue 1, p34 

    The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins...

  • Tumor Vaccines: A Role in Preventing Recurrence in Melanoma? Sabel, M.S.; Sondak, V.K. // American Journal of Clinical Dermatology;2002, Vol. 3 Issue 9, p609 

    Patients presenting with thick primary melanomas or those with regional nodal metastases have a high risk of recurrence after surgery alone. Chemotherapy has limited efficacy in the adjuvant setting, and while the use of high-dose interferon in the adjuvant setting has been reported to improve...

  • Advancing Gene Therapies for Immune Response to Cancer.  // Drug Discovery & Development;Oct2004, Vol. 7 Issue 10, p23 

    Reports on the four cancer vaccine immunotherapy programs of Transgene SA focusing on two cancer-associated antigens, the human papilloma virus proteins and the skin cancer-associated antigen MUC1. Functions of the delivered viral vectors; Gene expression of the protein within the tumors.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics